Campbell Wealth Management Buys 1,724 Shares of Eli Lilly and Company (NYSE:LLY)

Campbell Wealth Management grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 209.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,547 shares of the company's stock after acquiring an additional 1,724 shares during the period. Eli Lilly and Company comprises approximately 0.2% of Campbell Wealth Management's investment portfolio, making the stock its 25th biggest holding. Campbell Wealth Management's holdings in Eli Lilly and Company were worth $1,485,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Lipe & Dalton purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $36,000. St. Johns Investment Management Company LLC raised its position in shares of Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company's stock worth $39,000 after acquiring an additional 37 shares in the last quarter. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $40,000. Finally, O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company's stock valued at $44,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $6.19 during mid-day trading on Tuesday, reaching $763.89. The company had a trading volume of 1,955,605 shares, compared to its average volume of 3,034,869. The stock has a market capitalization of $726.01 billion, a P/E ratio of 112.34, a PEG ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The stock has a 50 day moving average of $760.79 and a two-hundred day moving average of $680.10. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.62 earnings per share. On average, analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 76.58%.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an "outperform" rating in a research report on Wednesday, May 1st. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a report on Friday, March 1st. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a report on Thursday, April 11th. Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, DZ Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.